Project Grant K01AI193070
Award Date 9/19/25
Completion Date 8/31/30
Dollars Obligated $190K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This federal Project Grant award, valued at $448,573, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant aims to develop analytical tools to address challenges in vaccine efficacy trials, such as diverse baseline immunity in target populations and the impact of emerging variants on vaccine-induced immunity. Key objectives include: 1) Developing an immunogenicity model to predict...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $176,738 to Trustees of Boston University (dba Boston University Medical Campus) to conduct research on optimizing vaccinations in Malawi, a sub-Saharan African country. The key goals are to train junior investigators to assess the longevity of antibody and memory cell responses induced by the SARS-CoV-2 Ad26.COV2-S vaccine, the contribution of...
- This Project Grant award, valued at $711,555.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The overarching goal is to contribute to the fundamental understanding of the spatiotemporal transmission dynamics and control of vaccine-preventable childhood infections through the development of an integrative modeling framework that combines traditional mechanistic models...
- The Project Grant award of $208,875.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Duke University to develop a multivalent mRNA HIV vaccine targeting recently circulating subtype C viruses. The central goal is to mature V2-apex precursor B cells and generate broadly neutralizing antibodies (bNAbs) that can neutralize diverse HIV strains, including subtype C, through a prime-boost vaccination...
- This $437,477 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop a human lymph node-on-a-chip microphysiological system for evaluating the effectiveness of vaccines against infectious diseases. The project, to be conducted by New York University (NYU) over a period from June 2025 to May 2027, seeks to address the lack of reliable preclinical models that can accurately replicate human adaptive...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,225,986 Cooperative Agreement on January 23, 2025 to the University of Chicago under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The project aims to develop computational models that describe the conditions under which strong, durable, and broadly protective adaptive immune responses to influenza vaccination arise, particularly in individuals with prior exposure to the virus....
- This federal Project Grant award of $462,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the Albert Einstein College of Medicine to design improved T cell epitopes for developing more effective T cell vaccines and therapies. The research aims to identify key molecular features and T cell receptor interaction patterns that promote the generation of superior memory CD8+ T cells with stem cell-like...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $929,500 to the Icahn School of Medicine at Mount Sinai to investigate the mechanisms of action for mRNA-based and Newcastle Disease Virus (NDV)-based COVID-19 vaccine platforms in inducing mucosal immune responses. The researchers aim to understand how these vaccine platforms can elicit long-lasting protective systemic and mucosal immunity...
- This $822,015 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of novel statistical methods to address challenges in studying public health interventions for infectious diseases like HIV/AIDS and COVID-19. The research aims to tackle issues related to network dependence, confounding, and missing data that commonly occur in such studies. The University of...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,379,954 to the Scripps Research Institute to conduct research focused on engineering durable immunity and optimizing HIV vaccine parameters to drive long-lived plasma cell development. The overarching goal is to discover an effective HIV vaccine that can induce protective immunity lasting for years...